Sanduzzi-Zamparelli M - Search Results

1

International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance.

Singal AG, Sanduzzi-Zamparelli M, Nahon P, Ronot M, Hoshida Y, Rich N, Reig M, Vilgrain V, Marrero J, Llovet JM, Parikh ND, Villanueva A. Singal AG, et al. Among authors: sanduzzi zamparelli m. J Hepatol. 2023 Jul;79(1):226-239. doi: 10.1016/j.jhep.2023.02.022. Epub 2023 Feb 26. J Hepatol. 2023. PMID: 36854345 Clinical Trial.

2

The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.

Sanduzzi Zamparelli M, Compare D, Coccoli P, Rocco A, Nardone OM, Marrone G, Gasbarrini A, Grieco A, Nardone G, Miele L. Sanduzzi Zamparelli M, et al. Int J Mol Sci. 2016 Jul 29;17(8):1225. doi: 10.3390/ijms17081225. Int J Mol Sci. 2016. PMID: 27483246 Free PMC article. Review.

3

Alcoholic disease: liver and beyond.

Rocco A, Compare D, Angrisani D, Sanduzzi Zamparelli M, Nardone G. Rocco A, et al. World J Gastroenterol. 2014 Oct 28;20(40):14652-9. doi: 10.3748/wjg.v20.i40.14652. World J Gastroenterol. 2014. PMID: 25356028 Free PMC article. Review.

4

The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.

Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G. Sanduzzi Zamparelli M, et al. United European Gastroenterol J. 2017 Nov;5(7):944-953. doi: 10.1177/2050640617705576. Epub 2017 May 8. United European Gastroenterol J. 2017. PMID: 29163959 Free PMC article. Review.

5

Preoperative work-up.

Compare D, Nardone OM, Sanduzzi-Zamparelli M, Nardone G. Compare D, et al. Ann Ital Chir. 2013 Sep-Oct;84(5):495-500. Ann Ital Chir. 2013. PMID: 24141228

6

New Systemic Treatments in Advanced Hepatocellular Carcinoma.

Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M. Sanduzzi-Zamparelli M, et al. Liver Transpl. 2019 Feb;25(2):311-322. doi: 10.1002/lt.25354. Liver Transpl. 2019. PMID: 30317696 Review.

7

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.

Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M. Díaz-González Á, et al. Aliment Pharmacol Ther. 2019 Mar;49(5):482-491. doi: 10.1111/apt.15088. Epub 2019 Jan 29. Aliment Pharmacol Ther. 2019. PMID: 30695819

8

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents.

Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Sanduzzi-Zamparelli M, et al. Viruses. 2019 May 1;11(5):406. doi: 10.3390/v11050406. Viruses. 2019. PMID: 31052463 Free PMC article. Review.

9

Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply.

Sanduzzi-Zamparelli M, Sapena V, Bruix J, Reig M. Sanduzzi-Zamparelli M, et al. Aliment Pharmacol Ther. 2020 Jan;51(1):192. doi: 10.1111/apt.15572. Aliment Pharmacol Ther. 2020. PMID: 31850569 No abstract available.

10

Controversies in the management of hepatocellular carcinoma.

Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Forner A, et al. JHEP Rep. 2019 Mar 18;1(1):17-29. doi: 10.1016/j.jhepr.2019.02.003. eCollection 2019 May. JHEP Rep. 2019. PMID: 32039350 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page